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Patent Settlement Cases
Year Companies Investigated Practice Country Fines
2016 GSK & Generics Illegal patent settlement 
agreements 
UK £45 million
2014 Servier & 
Generics
Illegal patent settlement 
agreements and illegal acquisition 
of a competing technology
EU €427.7 million
2013 Lundbeck & 
Generics







A.No limitation on 
competitor entry
(low risk)
B. Limitation on 
competitor entry
B.2. Value transfer to the 
competitor
(high risk)
B.1. No value transfer to 
the competitor
(low risk unless originator 
knows its patent is invalid or 
not infringed or if the 
restrictions on the 
competitor exceed the 
scope of the patent)
4The Commission’s Simplistic Analysis
Question 1: What is the counterfactual?  Generic enters and wins in 
litigation?  Less restrictive settlement?
Question 2: Has the Commission proven that its counterfactual is likely (or 
– in a by object case – so likely that a detailed assessment is 
redundant)?
5Many Counterfactuals Are Possible
Originator  Wins 
Injunction and on 
the Merits
Generic Decides 
Not to Enter Due 
to Patent Risks





Generic Enters At 
Risk and Loses in 
Litigation
Relevance of Reverse Payment
 Is the direction of the payment relevant?
• Commission:  reverse payment is anti-competitive because it suggests 
that Originator must think that it is likely to lose in litigation, so it must 
make a payment to keep Generic off the market
• But direction of payment is a red herring – it is a function of the parties’ 
relative bargaining positions and does not necessarily reflect the 
strength of the parties’ claims.
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Relevance of Reverse Payment
 Asymmetry of risk:
Reverse payment by Originator to Generic simply reflects asymmetry
of risk – even if Originator very likely to win, this asymmetry means
that it may not want to take a chance of losing.
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Relevance of Reverse Payment
 Key factors creating asymmetry of risk:
• Originator may face mandatory price reductions in 
jurisdiction of the litigation.
• Originator may face cascading price reductions in 
other jurisdictions due to reference pricing.
• Originator may incur significant damages due to 
length of litigation that it may have difficulty 
recovering.
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